| Richard F Ammar Jr, MD | |
|
3001 E President George Bush Hwy Ste 175, Richardson, TX 75082-3551 | |
| (214) 635-5701 | |
| (844) 289-7691 |
| Full Name | Richard F Ammar Jr |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 33 Years |
| Location | 3001 E President George Bush Hwy Ste 175, Richardson, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245210327 | NPI | - | NPPES |
| 305453806 | Medicaid | TX |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Richardson Medical Center | Richardson, TX | Hospital |
| Baylor Scott & White The Heart Hospital - Plano | Plano, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Heartplace Pllc | 2769386473 | 76 |
| Cardiac Cath Lab Of Collin County, Lp | 2961780382 | 4 |
News Archive
Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.
Research from the Perelman School of Medicine at the University of Pennsylvania and Massachusetts General Hospital (MGH) reveals that sons of male rats exposed to cocaine are resistant to the rewarding effects of the drug, suggesting that cocaine-induced changes in physiology are passed down from father to son.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, granted final approval for the Company's Abbreviated New Drug Application, for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
› Verified 3 days ago
| Entity Name | Heartplace Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417117912 PECOS PAC ID: 2769386473 Enrollment ID: O20040504001080 |
News Archive
Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.
Research from the Perelman School of Medicine at the University of Pennsylvania and Massachusetts General Hospital (MGH) reveals that sons of male rats exposed to cocaine are resistant to the rewarding effects of the drug, suggesting that cocaine-induced changes in physiology are passed down from father to son.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, granted final approval for the Company's Abbreviated New Drug Application, for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
› Verified 3 days ago
| Entity Name | Cardiology Specialists Of North Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689984585 PECOS PAC ID: 1456535624 Enrollment ID: O20110412001054 |
News Archive
Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.
Research from the Perelman School of Medicine at the University of Pennsylvania and Massachusetts General Hospital (MGH) reveals that sons of male rats exposed to cocaine are resistant to the rewarding effects of the drug, suggesting that cocaine-induced changes in physiology are passed down from father to son.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, granted final approval for the Company's Abbreviated New Drug Application, for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
› Verified 3 days ago
| Entity Name | Cardiac Cath Lab Of Collin County, Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336596097 PECOS PAC ID: 2961780382 Enrollment ID: O20161104001409 |
News Archive
Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.
Research from the Perelman School of Medicine at the University of Pennsylvania and Massachusetts General Hospital (MGH) reveals that sons of male rats exposed to cocaine are resistant to the rewarding effects of the drug, suggesting that cocaine-induced changes in physiology are passed down from father to son.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, granted final approval for the Company's Abbreviated New Drug Application, for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard F Ammar Jr, MD 3001 E President George Bush Hwy Ste 175, Richardson, TX 75082-3551 Ph: (214) 635-5701 | Richard F Ammar Jr, MD 3001 E President George Bush Hwy Ste 175, Richardson, TX 75082-3551 Ph: (214) 635-5701 |
News Archive
Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.
Research from the Perelman School of Medicine at the University of Pennsylvania and Massachusetts General Hospital (MGH) reveals that sons of male rats exposed to cocaine are resistant to the rewarding effects of the drug, suggesting that cocaine-induced changes in physiology are passed down from father to son.
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, granted final approval for the Company's Abbreviated New Drug Application, for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
› Verified 3 days ago
Dr. Anjaneya Puppala, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 399 W Campbell Rd, Medical Plaza Bldg Ii Suite 304, Richardson, TX 75080 Phone: 972-238-9696 Fax: 972-238-9753 | |
Dr. Olusegun Adewole Oyenuga, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3001 E President George Bush Hwy Ste 175, Richardson, TX 75082 Phone: 972-941-3117 Fax: 844-289-7691 | |
Dr. Nadia Takieddine, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2831 E President George Bush Hwy, Richardson, TX 75082 Phone: 469-204-2021 Fax: 469-204-2036 | |
Dr. Dee Mcleod, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2435 N Central Expy Ste 805, Richardson, TX 75080 Phone: 469-453-1423 | |
Neil Nghi Phung, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 275 W Campbell Rd Ste 120, Richardson, TX 75080 Phone: 214-393-6877 Fax: 214-393-6879 | |
Jamie Xuan Le, FNP-C Internal Medicine Medicare: Medicare Enrolled Practice Location: 3413 Spectrum Blvd Ste 100, Richardson, TX 75082 Phone: 972-688-6868 | |
Krupa Patel, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2821 E President George Bush Hwy Ste 410, Richardson, TX 75082 Phone: 469-204-4800 |